Abdominal Fat ReductionAbdominal Fat Reduction
有病率: 54% of US adults have elevated waist circumference; visceral obesity increasing even among normal-weight individuals
Evidence-Ranked Ingredients
| 成分 | グレード | 研究数 | 効果の方向 | |
|---|---|---|---|---|
| Probiotics (Lactobacillus gasseri) | A | 5 | Positive | 詳細を見る → |
| Omega-3 | B | 21 | Positive | 詳細を見る → |
| Green Tea Extract (EGCG) | B | 8 | Positive | 詳細を見る → |
| DHEA | C | 5 | Positive | 詳細を見る → |
About
Waist circumference above 40 inches in men and above 35 inches in women is the conventional threshold for abdominal obesity, and roughly 54 percent of US adults exceed it. The measure matters because visceral fat, the depot surrounding the abdominal organs, behaves differently from subcutaneous fat: it is metabolically active, drains directly to the liver, and tracks with insulin resistance and cardiovascular risk markers more closely than total body weight does. Visceral accumulation is increasing even among people whose body mass index falls in the normal range. Four ingredients carry a grade against this endpoint here, from 39 studies and about 2,500 participants.
Probiotic Lactobacillus gasseri holds the only Grade A rating, on 5 studies and 400 participants. Its study base is small in absolute terms but unusually consistent, and it is one of the few probiotic strains examined for visceral rather than total fat, typically by computed tomography or dual-energy X-ray absorptiometry rather than by scale weight.
Omega-3 fatty acids follow at Grade B with the largest evidence base of the group, 21 studies and 1,329 participants, and green tea extract standardized for EGCG holds Grade B on 8 studies and 600 participants. DHEA carries Grade C on 5 studies and 200 participants, the narrowest base here and the one with the clearest hormonal implications, since it is an androgen precursor rather than a nutrient.
The drivers of central accumulation are partly behavioral and partly not. Raised cortisol, alcohol intake, trans-fat consumption, poor sleep, and sedentary routines are modifiable. Menopause and inherited fat-distribution patterns are not. Because the visceral depot responds to the same energy balance that governs total fat, none of the ingredients in this set is studied as an alternative to that balance; each is studied as an addition to it.
No paper in the shared evidence library is currently linked to this condition, so the account above rests on the recorded grades, study counts, and participant totals rather than on named trials. Two limits deserve emphasis. First, the endpoints are not interchangeable: waist circumference, waist-to-hip ratio, CT-measured visceral area, and DXA trunk fat measure related but distinct quantities, and a change in one does not imply an equivalent change in another. Second, participant totals in this set are modest, between 200 and 1,329 per ingredient, which constrains how firmly any effect size can be stated. Raised liver enzymes and insulin resistance frequently accompany central adiposity and are matters for clinical assessment in their own right.
Common Symptoms
Risk Factors
- Cortisol elevation
- Alcohol consumption
- Trans fat intake
- Menopause
- Sedentary lifestyle
- Poor sleep
- Genetic fat distribution patterns
Frequently Asked Questions
What supplements may help with Abdominal Fat Reduction?
How is the evidence for Abdominal Fat Reduction supplements graded?
How many studies on Abdominal Fat Reduction supplements have been reviewed?
What are common symptoms of Abdominal Fat Reduction?
Related Conditions
共通の研究済み成分を持つ症状
FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。